Zum Inhalt springenZur Suche springen

Publikationen 2016-jetzt

undefinedUrner S, Planas-Paz L, Hilger LS, Henning C, Branopolski A, Kelly-Goss M, Stanczuk L, Pitter B, Montanez E, Peirce SM, Mäkinen T, Lammert E. Identification of ILK as a critical regulator of VEGFR3 signalling and lymphatic vascular growth. EMBO. 2019 Jan; 38(2)

undefinedLorenz L, Axnick J, Buschmann T, Henning C, Urner S, Fang S, Nurmi H, Eichhorst N, Holtmeier R, Bódis K, Hwang JH, Müssig K, Eberhard D, Stypmann J, Kuss O, Roden M, Alitalo K, Häussinger D, Lammert E. Mechanosensing by ß1integrin induces angiocrine signals for liver growth and survival. Nature. 2018; 562(7725):128-132.

undefinedWelters A, Lammert E, Mayatepek E, Meissner T. Need for better diabetes treatment:The therapeutic potential of NMDA receptor antagonists. Klin. Padiatr. 2017 Jan; 229(1):14-20

undefinedScholz O, Welters A, Lammert E. Role of NMDA receptors in pancreatic islets. In: Hashimoto K (ed.) The NMDA Receptors. Humana Press 2017 pp121-134

undefinedEglinger J, Karsjens H, Lammert E. Quantitative assessment of angiogenesis and pericyte coverage in human cell-derived vasculature sprouts. Inflammation and Regeneration 2017 Jan; 37:2

undefinedKragl M, Schubert R, Karsjens H, Otter S, Bartosinska B, Jeruschke K, Weiss J, Chen C, Alsteens D, Kuss O, Speier S, Eberhard D, Müller D J, Lammert E. The biomechanical properties of an epithelial tissue determine the location of its vasculature. Nature Communications 2016 Dec; 7:13560

undefinedBelgardt B F, Lammert E. DYRK1A: A promising drug target for islet transplant-based diabetes therapies. Diabetes 2016 Jun; 65(6):1496-8

undefinedOtter S, Lammert E. Exciting times for pancreatic islets: glutamate signaling in endocrine cells. Trends Endocrinol Metab. 2016 Mar; 27(3):177-88

undefinedMarquard J, Stirban A, Schliess F, Sievers F, Welters A, Otter S, Fischer A, Wnendt S, Meissner T, Heise T, Lammert E. Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial. Diabetes Obes Metab. 2016 Jan;18(1):100-3